Date: 2021-6.24 Your Name: Hong Chang Manuscript Title: Clinical efficacy of RCA in CRRT: systematic review

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

-			
_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
0	pending		
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-6.24 Your Name: Yueying Gong Manuscript Title: Clinical efficacy of RCA in CRRT: systematic review

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for		
lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for		
lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for		
speakers bureaus, manuscript writing or educational events		-	XNone	
manuscript writing or educational events XNone 6 Payment for expert testimony XNone 7 Support for attending meetings and/or travel XNone 8 Patents planned, issued or pending XNone 9 Patticipation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone				
educational events X_None 6 Payment for expert testimony X_None 7 Support for attending meetings and/or travel X_None 8 Patents planned, issued or pending X_None 9 Participation on a Data Safety Monitoring Board or Advisory Board X_None 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None 11 Stock or stock options X_None 12 Receipt of equipment, X_None				
6 Payment for expert testimony XNone 7 Support for attending meetings and/or travel XNone 8 Patents planned, issued or pending XNone 9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone				
testimony				
7 Support for attending meetings and/or travel XNone 8 Patents planned, issued or pending XNone 9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	6		XNone	
meetings and/or travel		testimony		
meetings and/or travel				
8 Patents planned, issued or pending XNone 9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	7	Support for attending	XNone	
pending		meetings and/or travel		
pending				
pending				
pending				
pending	Q	Patents planned issued or	X None	
9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	0	-		
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	9		XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone				
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10		XNone	
group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone		-		
11 Stock or stock options XNone 12 Receipt of equipment, XNone		-		
12 Receipt of equipment, X_None		group, paid or unpaid		
12 Receipt of equipment, X_None	11	Stock or stock ontions	X None	
		Stock of Stock options		
	10	Dessint of aguinment	V Nono	
motorials drugs modical	12	materials, drugs, medical writing, gifts or other		
services				
13 Other financial or non- _X_None	13		XNone	
financial interests		financial interests		

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-6.24 Your Name: Caixia Li Manuscript Title: Clinical efficacy of RCA in CRRT: systematic review

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

-			
_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
0	pending		
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-6.24 Your Name: Zengwen Ma Manuscript Title: Clinical efficacy of RCA in CRRT: systematic review

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for		
lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for		
lectures, presentations, speakers bureaus, manuscript writing or educational events	5	Payment or honoraria for		
speakers bureaus, manuscript writing or educational events		-	XNone	
manuscript writing or educational events XNone 6 Payment for expert testimony XNone 7 Support for attending meetings and/or travel XNone 8 Patents planned, issued or pending XNone 9 Patticipation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone				
educational events X_None 6 Payment for expert testimony X_None 7 Support for attending meetings and/or travel X_None 8 Patents planned, issued or pending X_None 9 Participation on a Data Safety Monitoring Board or Advisory Board X_None 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None 11 Stock or stock options X_None 12 Receipt of equipment, X_None				
6 Payment for expert testimony XNone 7 Support for attending meetings and/or travel XNone 8 Patents planned, issued or pending XNone 9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone				
testimony				
7 Support for attending meetings and/or travel XNone 8 Patents planned, issued or pending XNone 9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	6		XNone	
meetings and/or travel		testimony		
meetings and/or travel				
8 Patents planned, issued or pending XNone 9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	7	Support for attending	XNone	
pending		meetings and/or travel		
pending				
pending				
pending				
pending	Q	Patents planned issued or	X None	
9 Participation on a Data Safety Monitoring Board or Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	0	-		
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Advisory Board XNone 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone	9		XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone				
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10		XNone	
group, paid or unpaid XNone 11 Stock or stock options XNone 12 Receipt of equipment, XNone		-		
11 Stock or stock options XNone 12 Receipt of equipment, XNone		-		
12 Receipt of equipment, X_None		group, paid or unpaid		
12 Receipt of equipment, X_None	11	Stock or stock ontions	X None	
		Stock of Stock options		
	10	Dessint of aguinment	V Nono	
motorials drugs modical	12	materials, drugs, medical writing, gifts or other		
services				
13 Other financial or non- _X_None	13		XNone	
financial interests		financial interests		

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: